About Us

Archives






Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

Posted: August 15, 2021 at 1:51 am


MONTREAL, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical research of TH1902 for the treatment of sortilin-positive triple negative breast cancer (TNBC) in the peer-reviewed journal Cancer Science, confirming the in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism.

Link:
Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

Related Post

No Comments

No comments yet.

Sorry, the comment form is closed at this time.